Responses
Psoriatic arthritis
Original research
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
Compose a Response to This Article
Other responses
No responses have been published for this article.